AMS Planning, Inc.は北大発認定スタートアップ企業です

AMS Planning, Inc.

AMS Planning, Inc. Advanced Medical Science Planning, Inc.

About us

Cure Better, Innovation

AMS is a venture-backed Nuclear Medicine start-up leading the transformation of Japan’s nuclear sector. In the wake of the 2011 Fukushima nuclear accident, AMS is pioneering a new generation of nuclear medicine technologies that address systemic inefficiencies, regulatory bottlenecks, and limited access within the domestic market — through a dual focus on clinical innovation and infrastructure advancement. With two integrated business divisions — Theranostics Development (TD) and Engineering Solutions (ES) — AMS is positioned to shape the future of precision healthcare across the country.

In its TD business, AMS is introducing next-generation PET diagnostics, including 68Ga-PSMA, and supporting the development of novel radiotherapeutics such as astatine-211 (211At) to meet growing demand for targeted oncology solutions. These efforts are grounded in AMS’s proprietary expertise in medical device development, radiochemistry, and regulatory strategy. The resulting innovations are aligned with global trends and address pressing needs in a domestic market seeking scalable, high-impact care modalities.

Complementing this, AMS’s ES business tackles a critical barrier in the delivery of nuclear medicine: the safe and efficient management of radioactive discharge. The company has developed a proprietary bedside filtration system that streamlines regulatory compliance, reduces operational burden, and significantly improves patient throughput by enabling faster discharge and more rapid room turnover. This empowers hospitals to treat more patients within existing infrastructure, drives revenue growth, and facilitates earlier discharge for patients. Additionally, the platform generates actionable clinical data to support treatment decision-making and ensure the safe handling of radioactive materials.

With a differentiated portfolio, strong regulatory alignment, and robust investor backing, AMS presents a compelling opportunity in Japan’s revitalized nuclear medicine sector — where cutting-edge innovation converges with urgent healthcare needs and long-term market growth.

The AMS Growth Flywheel

AMS Growth

Our growth strategy is built on a four-stage self-reinforcing loop. At the core: AMS Growth, driven by the following pillars:

1.Mitigation of Bottlenecks in Nuclear Medicine
We apply our platform capabilities to resolve infrastructure, regulatory, and operational constraints that limit the adoption of nuclear medicine.
2.Expansion of Nuclear Medicine Treatments
Removing barriers enables increased clinical deployment, improving patient access and institutional readiness.
3.Introduction of Innovative Drugs to the Market
We support the introduction and scaling of cutting-edge radiopharmaceuticals, bringing new therapeutic value to healthcare providers and patients.
4.Acceleration of Investment into the Sector
As treatment volumes and drug pipelines grow, capital flows into the domain increase—supporting further expansion and reinforcing AMS’s leadership position.

Each element of the flywheel strengthens the others. Our Engineering Solution act as a catalyst for system-level transformation, while our Theranostics Platform Business anchors us in market impact and revenue generation.

Strategic Value for Investors

・Exponential Growth Potential
The flywheel model is inherently scalable—each success accelerates the next phase of growth and amplifies shareholder value.
・Clear Market Positioning
AMS is uniquely positioned to lead Japan’s nuclear medicine evolution, bridging systemic challenges with innovation and execution.
・Balanced Business Architecture
Our dual-engine approach—combining platform innovation with therapeutic commercialization—creates defensibility and flexibility.

News

Member

AMS team is the right mix of passion and experience from diversified industries, including experts in nuclear medicine, business development, and regulatory affairs.
  • Yuichiro Sugawara, MBA (Representative Director, President and CEO)
    Suga founded AMS in 2019, motivated by minimally invasive therapy and Fukushima Daiichi Accident, which has led him to focus on nuclear medicine. Suga has 20 years of business development experience in TEPCO and other companies with various senior business management roles.
    Suga has a bachelor’s and a master’s degree in engineering from Waseda University and an MBA from the Washington University in Saint Louis, Olin School of Business.
  • Toshihide Kubo (Director and Chief Operating Officer)
    Kubo joined AMS in July 2019 as Director and Chief Operating Officer. Kubo has 30 years of strategic investment and business management experience at Marubeni corporation, including as an outside director of Given Imaging Ltd. (now Medtronic).
    Kubo has a bachelor’s degree in engineering from Keio University.
  • Hiroyuki Okada (Outside Director)
    Okada joined AMS as an outside director in December 2022. Okada joined TEPCO in 1996, where he was involved in the development of Next Generation Nuclear Reactors in the Nuclear Energy Division. He was then transferred to TNP Partners (VC), where he was in charge of hands-on support. With a deep understanding of "large enterprises and small business" and "business company and finance," he has accumulated much experience in strategic planning and implementation, from business composition to service and sales strategy.
    Okada has a B.S. in Materials Science and an M.S. in Nuclear Engineering from the Tokyo Institute of Technology and holds a Chief Nuclear Reactor Engineer license in Japan.
  • Komei Washino, Ph.D. (Chief Technology Officer)
    Washino joined AMS in Dec 2019 as Nuclear Medicine Technical Manager. Washino has 30 years of experience in drug development, research, and commercialization of innovative radiopharmaceuticals. Before AMS, Washino was a Director at Nihon Medi-Physics, held academic appointments as a research professor at Hokkaido University Graduate School of Medicine and visiting researcher at the National Institutes for Quantum and Radiological Science and Technology (QST).
    Dr. Washino received his DVM, Doctor of Veterinary Medicine, and Ph.D. from the Faculty of Veterinary Medicine, Hokkaido University.
  • Noriake Okamoto (Nuclear Medicine Academic Office Manager)
    Okamoto joined AMS in Feb 2019 as Nuclear Medicine Academic Office Manager. Okamoto has spent 40 years in commercial and business development roles in companies in the nuclear medicine sector, beginning his career with Daiichi-RI Pharma (Now Fujifilm Toyama Kagaku) in 1975, including as General Manager for Bristol-Myers Squibb and Dupont. Okamoto also held an academic appointment as a lecturer at CHIBA INSTITUTE OF SCIENCE, Faculty of Risk and Crisis Management, Department of Health and Medical Sciences.
    Okamoto holds a pharmacist license in Japan, a bachelor of pharmacy from Shizuoka Prefectural college of Pharmacy and was a research fellow at Pharmaceutical Science, Tokyo University.
  • Meizo Kusaka, Ph.D. (Regulatory Office Manager)
    Kusaka joined AMS in May 2020 as Regulatory Office Manager. Kusaka has 40 years of experience in regulatory and clinical affairs, beginning his career with Zeria Pharmaceutical KK in 1978, including managerial roles at Marion Merrell Dow K.K. (Now Aventis Pharma Co.), Bristol-Myers Squibb KK, St.Jude Medical Company, and ConvaTec Japan KK. Kusaka also holds an academic appointment as a lecturer at Kyoto Tachibana University, Faculty of Nursing.
    Kusaka received a bachelor of pharmacy from Nihon University, M.S., Pharmacy from Kitasato University, and Ph.D., Pharmacy from Hoshi University. Kusaka holds a pharmacist's license in Japan.
  • Keiichi Hirano (Chief Engineer)
    Hirano joined AMS in Sep 2023 as Chief Engineer. Hirano has 40 years of experience in the production of radiopharmaceuticals (GMP), which has been distributed all over Japan in a safe, stable, and reliable manner for many years; the development of several types of Radiopharmaceutical Synthesizer for the production of radiopharmaceuticals labeled with Ga67/I123/F18 and more recently At211, where he has collaborated with significant universities and hospitals dedicated to nuclear medicine in Japan.
    Before AMS, Hirano worked for Nihon Medi-Physics and its subsidiary.

Interview

Company

Name of company
Advanced Medical Science-Planning, Inc
Paid-In Capital
310,990,500 JPY
Description of business
Production, import, development and sales of
radio-isotopes and medical devices
Location
5-6-9-303, Shirokanedai, Minato-Ku,
Tokyo, 108-0071, Japan
Email Address